Vanda Pharmaceuticals Executive and Leadership Team

Behrouz Ahmadinejad, the Chief Executive Officer at Vanda Pharmaceuticals, directs the company's overarching strategy and operational execution. Ahmadinejad guides the organization's mission to develop innovative medicines, leveraging advanced technologies like genetics and genomics to accelerate drug discovery and clinical trials. This leadership role involves setting the strategic direction for commercialization efforts across North America, Europe, and Asia, ensuring alignment with the company's goal of improving patient lives. Overseeing all functional areas, Ahmadinejad ensures that research and development initiatives directly support the creation of novel therapeutic approaches and delivery methods. The Chief Executive Officer's focus remains on advancing medical research and drug development for various health conditions, driving Vanda Pharmaceuticals' impact in the global pharmaceutical industry. Behrouz Ahmadinejad's strategic vision solidifies the company's commitment to pioneering new treatments.

Mihael Polymeropoulos, the President, Chief Executive Officer & Chairman at Vanda Pharmaceuticals, provides executive leadership and strategic oversight across the organization. Polymeropoulos champions the company's core mission of developing innovative medicines, utilizing cutting-edge genetics and genomics to advance drug discovery and clinical trials. This multifaceted role involves guiding the company's global commercial strategies and ensuring novel therapeutic approaches are brought to market effectively. The President, Chief Executive Officer & Chairman's leadership extends to fostering a culture of continuous medical research and drug development, addressing diverse health conditions. Mihael Polymeropoulos's influence shapes Vanda Pharmaceuticals' commitment to improving patient lives through advanced pharmaceutical products and delivery methods. The Chairman's strategic direction ensures robust governance and long-term growth across North America, Europe, and Asia.

Paul Jones, the Chief Financial Officer at Vanda Pharmaceuticals, manages all financial operations and fiscal strategy. Jones oversees budgeting, financial planning, and resource allocation, ensuring the company's financial health supports its ambitious research and development goals. This role is critical in guiding the commercial strategies for innovative medicines, particularly in managing investments in advanced technologies like genetics and genomics. The Chief Financial Officer ensures that financial resources are effectively deployed to advance drug discovery, clinical trials, and the commercialization of novel therapeutic approaches. Paul Jones's financial acumen supports Vanda Pharmaceuticals' global presence across North America, Europe, and Asia, facilitating expansion and operational efficiency. By maintaining rigorous financial controls, Jones enables the company to continue its mission of improving patient lives through dedicated medical research and drug development.

Joakim Wijkstrom, the Senior Vice President, Chief Marketing Officer at Vanda Pharmaceuticals, directs all marketing and commercialization strategies. Wijkstrom leads the go-to-market initiatives for the company's innovative medicines, translating complex scientific advancements into accessible patient solutions. This position is pivotal in leveraging genetics and genomics insights to inform targeted marketing campaigns and product positioning. The Senior Vice President, Chief Marketing Officer oversees the promotion of novel therapeutic approaches and delivery methods, ensuring broad market reach across North America, Europe, and Asia. Joakim Wijkstrom's expertise drives Vanda Pharmaceuticals' efforts to improve patient lives by effectively communicating the value of its pharmaceutical products. This leadership role ensures that the company's commitment to advancing medical research and drug development resonates with healthcare providers and patients globally.